| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Children's Healthcare of Atlanta |
| Information provided by: | Children's Healthcare of Atlanta |
| ClinicalTrials.gov Identifier: | NCT00328185 |
Purpose
Transplantation is the preferred method of treating many forms of end-stage organ failure. While short-term results have improved, long-term outcomes remain inadequate. Myocardial fibrosis could potentially have an adverse effect on long-term cardiac function. We wish to study the degree of fibrosis to see if we can predict survival following pediatric heart transplantation.
| Condition |
|
Children Who Underwent Heart Transplantation Prior to Age 18 Received Care at Children's Healthcare of Atlanta |
| MedlinePlus related topics: | Heart Transplantation |
| Study Type: | Observational |
| Study Design: | Natural History, Longitudinal, Defined Population, Retrospective Study |
| Official Title: | Allograft Fibrosis: Its Regulation and Significance Following Pediatric Cardiac Transplantation |
Eligibility
| Ages Eligible for Study: | up to 18 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Georgia | |||||
| Children's Healthcare of Atlanta | |||||
| Atlanta, Georgia, United States, 30329 | |||||
| Children's Healthcare of Atlanta |
| Principal Investigator: | Brian E Kogon, MD | Emory University |
More Information
| Study ID Numbers: | 05-217 |
| First Received: | May 18, 2006 |
| Last Updated: | May 18, 2006 |
| ClinicalTrials.gov Identifier: | NCT00328185 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
